department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Qinlock · pharmadog

pharmadog
drugs
Qinlock

drug

patient view →

ripretinib

Marketedupdated 2mo ago

by Deciphera Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Qinlock

generic

ripretinib

indication

Gastrointestinal Stromal Tumor (GIST)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 58m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

May 15, 2027

312 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (41)

Oct 6, 2042method-of-use (U-3714)US 11779572
Feb 8, 2041method-of-use (U-3897)US 11969414
Dec 30, 2040formulationUS 11185535
Dec 30, 2040formulationUS 11395818
Dec 30, 2040formulationUS 11576903
Dec 30, 2040formulationUS 11612591
Dec 30, 2040formulationUS 11793795
Dec 30, 2040formulationUS 11801237
Dec 30, 2040formulationUS 11844788
Dec 30, 2040formulationUS 11850240
Dec 30, 2040formulationUS 11850241
Dec 30, 2040formulationUS 11896585
Dec 30, 2040formulationUS 11903933
Dec 30, 2040formulationUS 11911370
Dec 30, 2040formulationUS 11918564
Dec 30, 2040method-of-use (U-3219)US 11969415
Dec 30, 2040method-of-use (U-3957)US 12023328
Dec 30, 2040method-of-use (U-3219)US 12064422
Dec 30, 2040formulationUS 12213967
Dec 30, 2040formulationUS 12213968
Dec 30, 2040formulationUS 12226406
Dec 30, 2040formulationUS 12318374
Aug 12, 2040method-of-use (U-3153)US 10966966
Aug 12, 2040method-of-use (U-3330)US 11266635
Aug 12, 2040method-of-use (U-3381)US 11344536
Aug 12, 2040method-of-use (U-3416)US 11426390
Aug 12, 2040method-of-use (U-3423)US 11433056
Aug 12, 2040method-of-use (U-3382)US 11529336
Aug 12, 2040method-of-use (U-3442)US 11534432
Aug 12, 2040method-of-use (U-3537)US 11576904
Aug 12, 2040method-of-use (U-3750)US 11813251
Aug 12, 2040method-of-use (U-3960)US 12023325
Aug 12, 2040method-of-use (U-3959)US 12023326
Aug 12, 2040method-of-use (U-3958)US 12023327
Aug 12, 2040method-of-use (U-3153)US 12059410
Aug 12, 2040method-of-use (U-3971)US 12059411
Aug 12, 2040method-of-use (U-4183)US 12295944
Aug 12, 2040method-of-use (U-4191)US 12318373
May 15, 2034compositionUS 8461179
Jun 7, 2032method-of-use (U-3219)US RE48731
Jul 27, 2030compositionUS 81881134.1y

FDA exclusivities (1)

May 15, 2027ODE-298Orphan Drug (7y)312d

Trials studying ripretinib

phase2A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignanciesrecruitingn=94
phase2A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinibcompletedn=108
phase3A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinibactive not recruitingn=453
phase3A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinibactive not recruitingn=54
—Ripretinib (QINLOCK®) According to Current SmPCcompletedn=10
phase1A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GISTcompletedn=13